| Drug Type Gene therapy | 
| Synonyms RB 340, RB-340 | 
| Target | 
| Action antagonists, inhibitors | 
| Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Preclinical | United States  | - | 





